Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

    June 8, 2023

    Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

    June 7, 2023

    Biotechs face challenges as the industry’s annual bash returns to Boston

    June 5, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

      June 8, 2023

      Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

      June 7, 2023

      Biotechs face challenges as the industry’s annual bash returns to Boston

      June 5, 2023

      The Biotech Buying Bonanza: Why The FTC’s Amgen Battle Won’t Chill The Spree

      June 5, 2023

      China reaching for biotech breakthroughs in space

      June 2, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»Andrew Forrest backs Sydney biotech startup in $26 million raise
    Bio Technology

    Andrew Forrest backs Sydney biotech startup in $26 million raise

    yourbiotechBy yourbiotechMarch 1, 2023Updated:March 1, 2023No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email
    Sydney biotech company SpeeDx has raised $26 million for US expansion and to ramp up its diagnostic technologies for illnesses such as cancer.

    The raise included $5 million from Dr. Andrew Forrest’s new $250 million venture capital fund, Tenmile, which the WA mining billionaire launched last year with backing from his private investment company, Tattarang. Existing investors Platinum International Healthcare Fund and US medical fund Northpond Ventures also participated, 

    SpeeDx was launched in 2009 and took up residence at the deep tech incubator Cicada Innovations, developing a biotech that reads and interprets genetic information to diagnose diseases. It has offices in London and the US, and distributors across Europe.

    Its flagship products identify the bacteria behind sexually transmitted infections as well as reveal if there is resistance or sensitivity to antibiotics, giving doctors the ability to choose the most effective drug treatments. The company has licensing and partnership deals with Roche, GSK, Cepheid, BioCartis, and LabCorp. Its tests have changed standard clinical guidelines and medical practice in five countries. 

    During the COVID pandemic, SpeedX developed technologies to enhance the capabilities of standard PCR tests to detect genetic targets specific to a number of common cancers as well as infectious diseases caused by bacteria, viruses, and parasites. The demand for those products by medical diagnostic labs during the pandemic has helped the business ramp up its development pipeline.

    SpeeDx CEO Colin Denver said the capital raised will help accelerate technology and product development. “Our team of talented scientists is developing new technologies that promise to significantly broaden multiplex PCR capabilities to improve patient diagnoses,” he said. 

    Tenmile executive chair, Dr. Steve Burnell said SpeeDx is in a unique position to capitalize on the efficiency and productivity advantages offered by its technologies. “PCR-based diagnostics remain the gold standard, and we are excited about SpeeDx’s multiplexed solutions for large, high-throughput labs seeking to capitalize on expanded capacity generated during the pandemic,” he said. 

    Dr. Bianca Ogden, Platinum Investment Management’s portfolio director, and a SpeeDx director said the business “is really only getting started” on its global potential.  “Given the pandemic, there is now a large installed base of instruments that are in need of diagnostic tests, we call that a menu, and hence Speedx essentially has the goods to provide menu expansion for the large established companies,” she said. 

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleBiotech proved a surprisingly bright spot in 2022’s startup correction
    Next Article US biotech firm Reata’s stock zooms 175% after FDA nod
    yourbiotech
    • Website

    Related Posts

    Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

    June 8, 2023

    Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

    June 7, 2023

    Biotechs face challenges as the industry’s annual bash returns to Boston

    June 5, 2023

    The Biotech Buying Bonanza: Why The FTC’s Amgen Battle Won’t Chill The Spree

    June 5, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.